 weekli cisplatin-bas induct regimen extens non-smal cell lung cancer southwest oncolog group studi purpos phase II pilot studi dose-intens regimen weekli cisplatin activ non-cross-resist agent respons rate surviv time patient extens non-smal cell lung cancer patient cisplatin day mitomycin day vinblastin day continu infus hour day patient consolid therapi cisplatin etoposid regist patient elig evalu respons overal respons rate patient complet respons CR patient partial respons PR median surviv time month toxic profil differ standard-dos regimen regimen benefit standard-dos cisplatin regimen patient extens non-smal lung cancer weekli schedul dose-intens regimen accept toxic tumor approach